Literature DB >> 21849398

Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment.

Patsuree Cheebsumon1, Floris H P van Velden, Maqsood Yaqub, Virginie Frings, Adrianus J de Langen, Otto S Hoekstra, Adriaan A Lammertsma, Ronald Boellaard.   

Abstract

UNLABELLED: PET can be used to monitor response during chemotherapy and assess biologic target volumes for radiotherapy. Previous simulation studies have shown that the performance of various automatic or semiautomatic tumor delineation methods depends on image characteristics. The purpose of this study was to assess test-retest variability of tumor delineation methods, with emphasis on the effects of several image characteristics (e.g., resolution and contrast).
METHODS: Baseline test-retest data from 19 non-small cell lung cancer patients were obtained using (18)F-FDG (n = 10) and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) (n = 9). Images were reconstructed with varying spatial resolution and contrast. Six different types of tumor delineation methods, based on various thresholds or on a gradient, were applied to all datasets. Test-retest variability of metabolic volume and standardized uptake value (SUV) was determined.
RESULTS: For both tracers, size of metabolic volume and test-retest variability of both metabolic volume and SUV were affected by the image characteristics and tumor delineation method used. The median volume test-retest variability ranged from 8.3% to 23% and from 7.4% to 29% for (18)F-FDG and (18)F-FLT, respectively. For all image characteristics studied, larger differences (≤10-fold higher) were seen in test-retest variability of metabolic volume than in SUV.
CONCLUSION: Test-retest variability of both metabolic volume and SUV varied with tumor delineation method, radiotracer, and image characteristics. The results indicate that a careful optimization of imaging and delineation method parameters is needed when metabolic volume is used, for example, as a response assessment parameter.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21849398     DOI: 10.2967/jnumed.111.088914

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  30 in total

1.  On the assessment of spatial resolution of PET systems with iterative image reconstruction.

Authors:  Kuang Gong; Simon R Cherry; Jinyi Qi
Journal:  Phys Med Biol       Date:  2016-02-11       Impact factor: 3.609

2.  Optimising delineation accuracy of tumours in PET for radiotherapy planning using blind deconvolution.

Authors:  A Guvenis; A Koc
Journal:  Radiat Prot Dosimetry       Date:  2015-04-01       Impact factor: 0.972

3.  Intratumor distribution and test-retest comparisons of physiological parameters quantified by dynamic contrast-enhanced MRI in rat U251 glioma.

Authors:  Madhava P Aryal; Tavarekere N Nagaraja; Stephen L Brown; Mei Lu; Hassan Bagher-Ebadian; Guangliang Ding; Swayamprava Panda; Kelly Keenan; Glauber Cabral; Tom Mikkelsen; James R Ewing
Journal:  NMR Biomed       Date:  2014-08-14       Impact factor: 4.044

4.  Measurement of metabolic tumor volume: static versus dynamic FDG scans.

Authors:  Patsuree Cheebsumon; Floris Hp van Velden; Maqsood Yaqub; Corneline J Hoekstra; Linda M Velasquez; Wendy Hayes; Otto S Hoekstra; Adriaan A Lammertsma; Ronald Boellaard
Journal:  EJNMMI Res       Date:  2011-12-14       Impact factor: 3.138

Review 5.  Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?

Authors:  Hyung-Jun Im; Tyler Bradshaw; Meiyappan Solaiyappan; Steve Y Cho
Journal:  Nucl Med Mol Imaging       Date:  2017-09-19

6.  Multi-level otsu method to define metabolic tumor volume in positron emission tomography.

Authors:  Hyung-Jun Im; Meiyappan Solaiyappan; Inki Lee; Tyler Bradshaw; Najat C Daw; Fariba Navid; Barry L Shulkin; Steve Y Cho
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-12-20

7.  Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy.

Authors:  Jacques-Antoine Maisonobe; Camilo A Garcia; Hatem Necib; Bruno Vanderlinden; Alain Hendlisz; Patrick Flamen; Irène Buvat
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-14       Impact factor: 9.236

8.  Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer.

Authors:  Virginie Frings; Adrianus J de Langen; Maqsood Yaqub; Robert C Schuit; Astrid A M van der Veldt; Otto S Hoekstra; Egbert F Smit; Ronald Boellaard
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488

9.  Reproducibility and reliability of anti-3-[¹⁸F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis.

Authors:  Oluwaseun A Odewole; Oyeladun A Oyenuga; Funmilayo Tade; Bital Savir-Baruch; Peter T Nieh; Viraj Master; Zhengjia Chen; Xiaojing Wang; Ashesh B Jani; Leah M Bellamy; Raghuveer K Halkar; Mark M Goodman; David M Schuster
Journal:  Mol Imaging Biol       Date:  2015-04       Impact factor: 3.488

Review 10.  The developing role of FDG PET imaging for prognostication and radiotherapy target volume delineation in non-small cell lung cancer.

Authors:  Tom Konert; Jeroen B van de Kamer; Jan-Jakob Sonke; Wouter V Vogel
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.